Freerksen E, Seydel J K
Med. Pharm. Chemistry, Borstel Research Institute, Fed. Rep. of Germany.
Arzneimittelforschung. 1992 Oct;42(10):1243-5.
The usefulness of clofazimine (CLO, CAS 2030-63-9) in the treatment of mycobacterial infections with special emphasis on treatment of leprosy is critically discussed. Skin discolouration which decreases compliance, placenta passage, excretion in mother's milk which endanger the embryo or baby respectively, saturation kinetics in absorption and difficulties to determine free drug concentration are severe problems. The observed antagonism in the combination of CLO with other drugs, especially with dapsone, is another argument against its application in the therapy of mycobacterial infections. In Germany CLO has not been approved by the Bundesgesundheitsamt.
对氯法齐明（CLO，化学物质登记号2030 - 63 - 9）在治疗分枝杆菌感染尤其是麻风病治疗中的效用进行了批判性讨论。皮肤变色会降低患者依从性，药物可通过胎盘以及经母乳排泄，分别对胚胎或婴儿构成危害，吸收过程中的饱和动力学以及难以测定游离药物浓度都是严重问题。观察到的氯法齐明与其他药物（尤其是与氨苯砜）联合使用时的拮抗作用，是反对其用于分枝杆菌感染治疗的另一个理由。在德国，氯法齐明尚未获得联邦卫生局的批准。
